<DOC>
	<DOCNO>NCT00637286</DOCNO>
	<brief_summary>The purpose study determine useful effective use ZOMIG-ZMT™ ( zolmitriptan ) 5.0 mg ZOMIG® Nasal Spray ( zolmitriptan ) 5.0 mg patient , treat migraine period 6 month</brief_summary>
	<brief_title>ZAP , US . Zomig Appropriate Primary Care</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Have establish diagnose migraine age onset less 50 year Have experience average least 1 migraine headache per month previous three month Be able differentiate migraine nonmigraine headache Use triptan within last 12 month use MAOA inhibitor , methysergide methylergonovine 2 week enter study . History basilar , ophthalmoplegic hemiplegic migraine headache potentially serious neurological condition associate headache History , symptom , significant risk factor ischaemic heart cardiovascular disease , include coronary vasospasm , cardiac accessory conduction pathways arrhythmias uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Zolmitriptan</keyword>
	<keyword>ZOMIG</keyword>
	<keyword>migraine</keyword>
	<keyword>headache response</keyword>
	<keyword>headache</keyword>
	<keyword>headache pain</keyword>
	<keyword>MIDAS</keyword>
	<keyword>HCPC</keyword>
</DOC>